# Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder

> **NCT00142961** · PHASE2 · COMPLETED · sponsor: **New York State Psychiatric Institute** · enrollment: 2 (actual)

## Conditions studied

- Attention Deficit Disorder With Hyperactivity
- Marijuana Abuse

## Interventions

- **DRUG:** Atomoxetine
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00142961
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2019-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00142961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00142961, "Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT00142961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*